Reply by Authors

J Urol. 2023 May;209(5):900. doi: 10.1097/JU.0000000000003195.02. Epub 2023 Apr 7.

Authors

Mark D Tyson¹, David Morris², Juan Palou³, Oscar Rodriguez³, Maria Carmen Mir⁴, Rian J Dickstein⁵, Félix Guerrero-Ramos⁶, Kristen R Scarpato⁷, Jason M Hafron⁸, Edward M Messing⁹, Christopher J Cutie¹⁰, John C Maffeo¹⁰, Bradley Raybold¹¹, Albert Chau¹², Katharine A Stromberg¹³, Kirk A Keegan^{7

10}

Affiliations

¹ Mayo Clinic Arizona, Phoenix, Arizona.
² Urology Associates, Nashville, Tennessee.
³ Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁴ Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
⁵ Chesapeake Urology, Baltimore, Maryland.
⁶ University Hospital 12 de Octubre, Madrid, Spain.
⁷ Vanderbilt University Medical Center, Nashville, Tennessee.
⁸ Michigan Institute of Urology, Troy, Michigan.
⁹ University of Rochester, Rochester, New York.
¹⁰ Janssen Research & Development, Lexington, Massachusetts.
¹¹ Janssen Research & Development, Spring House, Pennsylvania.
¹² Datacision Limited, London, United Kingdom.
¹³ Janssen Research & Development, Raritan, New Jersey.

PMID: 37026638
DOI: 10.1097/JU.0000000000003195.02

No abstract available

Publication types

Comment